tolvaptan has been researched along with hydralazine in 2 studies
| Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) | Studies (hydralazine) | Trials (hydralazine) | Recent Studies (post-2010) (hydralazine) |
|---|---|---|---|---|---|
| 967 | 172 | 786 | 4,580 | 364 | 393 |
| Protein | Taxonomy | tolvaptan (IC50) | hydralazine (IC50) |
|---|---|---|---|
| Myeloperoxidase | Homo sapiens (human) | 1.265 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 3.649 | |
| Lactoperoxidase | Bos taurus (cattle) | 1.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dunlap, ME; Ibrahim, OA | 1 |
2 review(s) available for tolvaptan and hydralazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers?
Topics: Acetanilides; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Mineralocorticoid Receptor Antagonists; Piperazines; Pyridines; Ranolazine; Tetrazoles; Tolvaptan; Vasodilator Agents | 2005 |